ANEB · CIK 0001815974 · FY2025 live · 2025-06-30
Anebulo Pharmaceuticals, Inc.
View as
Model
Classic Z
FY2025
4.50
Zone
Safe
Prior
—
Market DD
—
1y PD
—
4.50
Z″ 6.63
Score 4.50 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.981.2 × = 1.18X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−6.081.4 × = −8.52X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.763.3 × = −2.51X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
23.900.6 × = 14.34X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings.
Meridian Rank
65.45
0–100 · Classic Z family
Book standing
90
Year change
—
Market PD
—
O-score
0
Events on this name
Same published rows as Today.
Approaching grey
watch · 41
- Live score: — → 4.50
- Cut: — → 1.80
Overview
rule-v1
Anebulo Pharmaceuticals, Inc. is on classic Z at 4.50 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print; retained earnings / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers. Buybacks can send retained earnings negative at otherwise healthy issuers. X4 is book equity.
Book screen Safe; market PD —. Market PD has not been priced on this name.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 89th percentile in Healthcare.
Filing line items
Current assets
$12M
Total assets
$12M
Current liabilities
$0
Total liabilities
$488K
Working capital
$12M
Retained earnings
−$74M
EBIT
−$9M
Total sales
$0
Book equity
$12M
Accession 0001493152-25-016015. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-06-30). Classic Z is the live score. View as is a display overlay. X4 is book equity. Pulled 13 Sept 2026.